tbuckley/cabot-search huggingface dataset:
SAT0529 Relationship between Changes in Serum Urate and Bone Mineral Density during Treatment with Thiazide Diuretics: Secondary Analysis from A Randomised Controlled Trial
Authors: N. Dalbeth, G.D. Gamble, A. Horne, I.R. Reid
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Recent observational studies have reported that serum urate (SU) concentrations positively correlate with bone mineral density (BMD), and that higher SU concentrations are associated with reduced risk of fractures. Thiazide diuretics slow bone loss in healthy older adults, and have been associated with reduced incidence of fracture. These agents also increase SU concentrations. We hypothesized that changes in SU concentrations predict changes in BMD during treatment with thiazide diuretics. <h3>Objectives</h3> To examine the relationship between change in SU and change in BMD during treatment with thiazide diuretics. <h3>Methods</h3> We analysed data from a two-year double-blind randomised controlled trial of hydrochlorothiazide (50mg per day) and placebo in normal post-menopausal women<sup>1</sup>. The relationship between change in SU and BMD after two years of treatment was examined using Spearman correlation and linear regression models (n=124 participants). <h3>Results</h3> After two years, total body BMD increased in the hydrochlorothiazide group by 0.0056g/cm<sup>2</sup> and reduced in the placebo group by 0.0032g/cm<sup>2</sup> (between group difference P=0.0034). SU concentration increased in the hydrochlorothiazide group by 0.036mmol/L and reduced in the placebo group by 0.0059mmol/L (between group difference P&lt;0.0001). There was no relationship between the change in total body BMD and change in SU concentration (for entire study population, r=0.13; for hydrochlorothiazide group, r=0.03; and for placebo group, r=-0.005; P≥0.13 for all). There was no difference in the regression line slopes for change in total body BMD and change in SU in the thiazide and placebo groups (P<sub>compare slopes</sub>=0.997). In multiple linear regression models, the effects of hydrochlorothiazide on total body BMD persisted after including baseline SU and change in SU in the model (P<sub>treatment</sub>=0.01), with no independent influence of change in SU (P<sub>change in SU</sub>=0.96). Similar results were observed for BMD at individual sites (legs, mid-forearm, ultradistal forearm, lumbar spine and femoral neck). <h3>Conclusions</h3> The effects of hydrochlorothiazide on BMD occur independently of the effects on SU concentrations. <h3>References</h3> Reid IR, Ames RW, Orr-Walker BJ, et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med 2000;109:362-70. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3395
James Montgomery Dunlop
Authors: Douglas Dunlop
Journal: BMJ (2016)

James Montgomery Dunlop (“Jim”) left school at 17 and volunteered for the Royal Air Force, where he was a nurse. After a varied career with the Department of Agriculture touring Scotland as a potato inspector, training as an actuary with the Scottish Provident Institution, and working in the Blood Transfusion Department at Edinburgh Royal Infirmary, Jim discovered his true vocation and went to Trinity College Dublin to study medicine in 1954.

At college he discovered his innate …
759 CLINICAL CHARACTERISTIC OF PATIENTS WITH NON-B, NON-C HEPATOCELLULAR CARCINOMA - COMPARISON BETWEEN ALCOHOLIC AND NON-ALCOHOLIC
Authors: S. Usui, H. Saito, H. Ebinuma, P. Chu, N. Nakamoto, Y. Yamagishi, T. Kanai, T. Hibi
Journal: Journal of Hepatology (2012)
Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models Of CLL – The Role Of Abl and Btk
Authors: Rachel Thijssen, Christian R Geest, Martin FM de Rooij, Nora Liu, Bogdan I Florea, Katinka Weller, Hermen S Overkleeft, Marinus H.J. Van Oers, Marcel Spaargaren, Arnon P. Kater, Eric Eldering
Journal: Blood (2013)
P523 SAFETY AND EFFICACY OF AN AUTOMATED LOW FLOW ASCITES (ALFA) PUMP IN CIRRHOTIC PATIENTS WITH REFRACTORY ASCITES
Authors: A. De Gottardi, V. Banz, F. Storni, G. Stirnimann, N. Semmo, C. Engelmann, A.-C. Piguet, S. Whittaker, F. Lammert, T. Berg, S. Zeuzem, J. Cordoba, J.-F. Dufour
Journal: Journal of Hepatology (2014)
EXPERIENCE WITH A QUANTITATIVE ONCOLOGIC IMAGING AND MIRDOSE3 DOSIMETRY PROTOCOL
Authors: W. D. Erwin, M. W. Groch, A. M. Zimmer, S. M. Spies
Journal: Clinical Nuclear Medicine (1997)

Scientific Abstracts: Central Chapter, Society Of Nuclear Medicine Meeting, April 11-13, 1997, Grand Geneva Resort, Lake Geneva, Wi
FRI0052 Serum level of total adiponectin independently predicts rapid radiographic disease progression in early rheumatoid arthritis: a cohort study.
Authors: J. Sellam, S. Kotti, M. Meyer, S. Fellahi, J.-P. Bastard, O. Meyer, F. Lioté, T. Simon, J. Capeau, F. Berenbaum
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Adipokines have recently emerged as pro-inflammatory mediators involved in the pathophysiology of rheumatoid arthritis (RA). <h3>Objectives</h3> To determine whether serum adipokine levels independently predicted early rapid radiographic disease progression (RRP) in early RA. <h3>Methods</h3> ELISA was used to assess baseline serum levels of total adiponectin, leptin and visfatin/NAMPT in the 632 patients from the French ESPOIR cohort who met the American College of Rheumatology-European League Against Rheumatism criteria for RA. We tested the association of serum adipokine levels and RRP defined as a change ≥ 5 in total Sharp-van der Heijde Score between inclusion and 1 year (ΔSHS≥5) corresponding to the destruction of one small joint (1) in univariate analysis and also after adjusting for all pertinent confounders (age, sex, body-mass-index, insulin resistance log(HOMA-IR), C-reactive protein level (logCRP), DAS28, log(HAQ score), rheumatoid factor and anti-CCP antibodies status, steroid use and radiographic evidence of RA damage at inclusion. Sensitivity <i>versus</i> the false positive frequency (1-specificity) for predicting radiographic disease progression with adiponectin levels was analysed by a receiver-operated characteristic (ROC) curve. The optimal cut-off point of adipokines level to identify patients with RRP was calculated using Youden index. <h3>Results</h3> In univariate analyse, there was a trend for association between serum level of adiponectin and RRP (odds ratio OR [95%confidence interval]=1.47 [0.98-2.20]; p=0.06). In multivariate model, serum adiponectin level was independently associated with ΔSHS≥5 (adjusted OR=2.0 [1.14-3.52], p=0.0165) (Table). Conversely, leptin level was associated with RRP only in univariate analyse (OR=0.73 [0.54-0.97]; p=0.03) and visfatin/NAMPT level displayed no association. Considering the ROC curve, the best serum adiponectin cut-off value level to predict ΔSHS ≥ 5 was 1.60 μg/mL (sensitivity=0.74 and specificity=0.73 and area under the ROC curve=0.76). <h3>Conclusions</h3> Serum adiponectin level is a simple and useful biomarker predicting early RRP in early RA independently of RA-confounding factors and metabolic status. Using the threshold of 1.6 μg/mL, patients with early RA at increased risk of early RRP can be identified. <h3>References</h3> Vastesaeger N et al. Rheumatology(Oxford) 2009,48:1114-21 <h3>Disclosure of Interest</h3> None Declared
SP0116 Improving the prevention of co-morbidity of lupus patients – a project of the german lupus patient organisation
Authors: B. Winkler-Rohlfing
Journal: Annals of the Rheumatic Diseases (2012)

The medical treatment of people with systemic lupus erythematosus has improved considerably during the last decades. Persons with the condition die less and less often because of the condition and death following a severe infection due to immunosuppressive medication has decreased in frequency. However, the number of patients dying because of arteriosclerosis has increased. As lupus patients have a higher risk to develop arteriosclerosis due to their condition and the necessary therapy, it is very important to influence as many risk factors as possible. In order to raise awareness with patients and doctors about the risk factors and possibilities of prevention, the lupus prevention passport has been developed. Using a traffic light code, the risk factors smoking, excess weight, high blood pressure, high glucose level and lack of exercise can be identified and evaluated. The passport contains an additional emergency section and a chart which allows the patient to carry with them their recent data and information about their medication. The use of the passport has been evaluated. The Lupus Erythematosus Self-help Organisation supports the use of the passport through a special internet platform www.lupus-pass.de. Further training was supposed to increase the use of the passport, which has partly succeeded. <h3>Disclosure of Interest</h3> None Declared
PTU-172 C-Myc as a Biomarker in Barrett’S Oesophagus: Abstract PTU-172 Table 1
Authors: S Varghese, C S Ross-Innes, P Lao-Sirieix, M O’Donovan, R C Fitzgerald
Journal: Gut (2013)

<h3>Introduction</h3> Identifying Barrett’s oesophagus (BE) patients at risk of progressing to oesophageal adenocarcinoma (EA) remains a challenge. Diagnosis of low grade dysplasia is limited by considerable intra and inter-observer variability and inflammation in biopsy samples can lead to a diagnosis of indefinite for dysplasia. Immunostaining using molecular biomarkers would therefore be useful as a diagnostic adjunct in the assessment of dysplasia. The Aim of this study was to identify and validate a molecular biomarker that can objectively determine dysplasia status and thereby determine cancer risk in BE. <h3>Methods</h3> Biomarkers of interest were identified through mining of a microarray gene expression dataset from 59 oesophageal samples with strict consensus diagnosis by expert pathologists [21 BE with no dysplasia (NDBE), 10 BE with low grade dysplasia (LGD), 13 BE with high grade dysplasia (HGD) and 8 EA]. Subsequent validation was performed on a BE tissue microarray (TMA) (60 NDBE, 19 LGD and 29 HGD), and EA TMA (n = 278). <h3>Results</h3> Seventy eight genes were differentially expressed between NDBE and HGD. c-MYC was selected as a top target as the expression levels progressively increased with dysplasia stage and cancer with a fold change of 2.46 between NDBE and HGD. mRNA expression levels were significantly higher in HGD and EA compared to NDBE (p &lt; 0.0001). Immunostaining for c-MYC was positive in 25 out of 29 cases of HGD with a sensitivity 86% of and a specificity of 97% (Table 1). 10 out of 19 LGD stained positive for MYC. 254 out of 278 (91%) EA cases showed significant c-MYC protein expression. Among the 19 LGD samples, 9 had HGD in the BE segment and 7 of these were positive for c-MYC. Strong c-MYC staining was also observed in areas regarded as indefinite for dysplasia which were adjacent to areas of HGD. Table 1. Immunohistochemistry for c-MYC in oesophageal samples. NDBE: Non-dysplastic Barrett’s oesophagus, LGD: Low-grade dysplasia, HGD: High grade dysplasia. <h3>Conclusion</h3> Immunohistochemistry for c-MYC is a promising molecular biomarker in Barrett’s oesophagus. It could also enable better risk stratification in patients with samples in the LGD and indefinite for dysplasia categories. <h3>Disclosure of Interest</h3> None Declared.
Long-Term Efficacy and Safety of Cyclosporine in Renal-Transplant Recipients
Authors: James F. Burke, John D. Pirsch, Eleanor L. Ramos, Daniel R. Salomon, Donald M. Stablein, David H. Van Buren, John C. West
Journal: New England Journal of Medicine (1994)

The safety of long-term immunosuppression with cyclosporine in renal-transplant recipients is not well understood. This drug may cause a progressive toxic nephropathy, but it also preserves renal function because it prevents rejection. To determine the effect of cyclosporine on renal function and graft rejection, we conducted a retrospective analysis of data on 1663 renal-transplant recipients at six centers.
S122 The M1 macrophage phenotype accentuates TGF- 1 driven epithelial to mesenchymal transition (EMT) via the secretion of TNF 
Authors: L. A. Borthwick, M. Brodlie, G. E. Johnson, C. Ward, J. Perry, P. A. Corris, A. De-Soyza, A. J. Fisher
Journal: Thorax (2010)

<h3>Introduction</h3> Obliterative Bronchiolitis (OB) is characterised by fibrotic obliteration of small airways which adversely affecting graft function and survival after lung transplantation. It has been shown in vitro and in vivo that primary bronchial epithelial cells (PBEC) from the transplanted lung can undergo epithelial to mesenchymal transition (EMT) and this process may contribute to the development of OB. We have shown that activated macrophages can disrupt epithelial wound repair by accentuating TGF-β1-driven EMT. We hypothesised that this effect might be limited to macrophages with an M1 phenotype and that their secretory products might be a target for limiting the inflammatory accentuation of EMT. <h3>Methods and materials</h3> The THP-1 monocytic cell line was stimulated with clinical isolates of <i>Pseudomonas aeruginosa</i> (PA) and the effect of the activated cells or conditioned media on TGF-β1-driven EMT assessed in PBEC (Western blotting, confocal microscopy). In addition, THP-1 cells were differentiated to an M1 phenotype by treatment with IFNγ and an M2 phenotype with IL-4/IL-13 and cytokine release (ELISA) and their effect on TGF-β1 driven EMT assessed. The effect of blocking TNFα secreted from activated THP-1 cells on EMT was assessed using an anti-TNFα antibody. <h3>Results</h3> Treatment with TGF-β1+activated THP-1 cells had no effect on EMT marker expression (p&gt;0.05 n=6). However, co-treatment with TGF-β1+conditioned media from activated THP-1 cells dramatically accentuated TGF-β1-driven EMT (p&lt;0.05 n=6). M1 differentiated THP-1 cells released 8.4-fold more TNFα and 8.1-fold more IL-1β than M2 cells (p&lt;0.05, n=3). Conditioned media from M1, but not M2, cells dramatically accentuated TGF-β1 driven EMT (p&lt;0.05 n=6). Blocking TNFα in the conditioned media from THP-1 cells significantly inhibits the decrease in E-cadherin (39%±4%) and the increase in vimentin (59%±18%) and fibronectin (72%±14%) expression (p&lt;0.05, n=5). <h3>Conclusion</h3> The secretory products of M1, but not M2, macrophages significantly accentuate TGF-β1 driven EMT. TNFα appears to be a major constituent of this accentuating action. This raises the possibility that either TNFα targeted therapies or modulation of macrophage phenotype may inhibit the inflammatory accentuation of EMT in airway epithelium.
Extensive Cutaneous Sarcoidosis
Authors: GHANSHYAM KALANI, HITEN MALDE
Journal: Clinical Nuclear Medicine (1996)

A 32-year-old woman with biopsy proven sarcoidosis was referred for Ga-67 imaging. In addition to systemic manifestations of sarcoidosis, the patient also had multiple skin nodules. Ga-67 imaging showed bilateral, symmetric increased uptake in the parotid glands. Increased tracer uptake was also noted in both supraclavicular, right paratracheal, and bilateral hilar regions consistent with lymphadenopathy. In addition, multiple foci of increased uptake were noted diffusely throughout all four extremities involving the subcutaneous tissues. Punch biopsy of one of the skin nodules demonstrated non-caseating granulomatous dermatitis and panniculitis consistent with sarcoidosis.
THU0406 Evaluation of periodontal parameters in patients with familial mediterranean fever:
Authors: S. Senel, V. Bostanci, H. Toker, S. Safak
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Familial Mediterranean fever (FMF) is a self-limiting autosomal recessive disorder characterized by recurrent attacks of fever and inflammation in the peritoneum, synovium or the pleura. It is not clear whether the periodontal tissues are also affected or not in the course of the disease. <h3>Objectives</h3> There are very limited data on periodontal parameters in patients with FMF. The aim of this study was to compare periodontal findings in FMF patients with healthy controls. <h3>Methods</h3> Eighty four patients (68 female, 16 male mean age: 32.2±1.2), diagnosed with FMF who applied from Rheumatology Department to Faculty of Dentistry Periodontology Department and 75 systemic healthy controls (59 female, 16 male, mean age: 30.9±1.2) were included in this study. DMFT (decayed, missing, filled teeth) values, plaque index (PI), gingival index (GI), probing depth (PD), clinical attachment level (CAL), radiographic findings were evaluated. <h3>Results</h3> At the end of the study statistical analyses showed no significant differences in DMFT values among groups (p&gt;0,05). PI and GI were significantly higher in the FMF group than in control group. PD and CALvalues were statically lower in FMF group than in control (p&lt;0,05) All results were shown in Table 1. <h3>Conclusions</h3> FMF patients can be more susceptible to periodontal diseases than the control group because of higher GI and PI values. Patients should receive dental treatments when necessary and be motivated to have an optimal oral hygiene. <h3>Disclosure of Interest</h3> None Declared
PWE-038 Significance Of Incidental Gastrointestinal Lesion On Pet Scan
Authors: F Leet, M Sharif, A Agrawal
Journal: Gut (2014)

<h3>Introduction</h3> CT PET scan with fluorine-18 (F-18) fluorodeoxyglucose (FDG), is a increasingly common investigation in the evaluation and management of several malignant and non-malignant conditions. <sup>(1–3)</sup>. The usefulness of this technique in diagnosing incidental gastrointestinal lesions in literature is scanty. The purpose of this study was to assess the usefulness of PET scan in detecting incidental significant gastrointestinal disease. <h3>Methods</h3> 696 PET scans were undertaken in Doncaster and Bassetlaw NHS Trust from 2009 to 2012. The principal indications were malignancy (lung 57%, GI tract 16%, head and neck 7%, haematological 4%, breast 2%) and nonmalignant 11%, unknown indication 3%. Of these, 44 cases (males 61%, median age 70) of incidental increased focal FDG uptake in gastrointestinal tract were detected. All patients underwent endoscopic procedure (Gastroscopy 10, Flexible sigmoidoscopy 10 and colonoscopy 24). <h3>Results</h3> 21 of 44 (48%) had polyps (malignant n = 3, tubulovillous adenoma n = 11, hyperplastic n = 6, not retrieved n = 1). Other pathologies included vascular lesions, inflammation, and diverticular disease. 11 patients had a false positive PET scan. The overall correlation between PET scanning and Endoscopic findings were found to be 75%. <h3>Conclusion</h3> PET scan is a valuable tool in localising incidental gastrointestinal pathology and a positive incidental finding merits further follow up endoscopy. The technique detected 6% new gastrointestinal lesions of which nearly half were polyps and two-thirds of these were malignant or adenomatous. <h3>References</h3> 1 Wong PS, Lau WF, Worth LJ, Thursky KA, Drummond E, Slavin MA, Hicks RJ. Clinically important detection of infection as an ‘incidental’ finding during cancer staging using FDG-PET/CT. <i>Int Med J</i> 2012;42(2):(176–83) 2 Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. <i>J Nucl Med.</i> 2001;42(suppl): 1S–93S 3 I Takayoshi, <i>et al</i>. Detection of unexpected additional primary malignancies with PET/CT. <i>J Nucl Med</i>. 2005;46(5):752–757 <h3>Disclosure of Interest</h3> None Declared.
SP0022 Food as Therapy – Supporting Healthy Choices
Authors: H. Thorseng
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> Healthy food and a healthy weight can make a difference and is important for people with rheumatic or musculoskeletal diseases (RMDs). There are many messages about how diet can affect RMDs. The Danish Reumatism Association supports people with RMDs and their relatives by collecting and providing neutral information about how to obtain a healthy diet and a healthy weight in relation to RMDs. The information is free either through our website, our mailbox or our hotline advice service. On the free helpline people with RMDs and their relatives can talk to a professional adviser e.g. a nutritionist. Furthermore, members of the organization can frequently read about food in relation to RMDs in our magazine. People with RMDs have several reasons to pay attention to what they eat. A healthy and balanced diet is essential to meet the body9s need for nutrients and to prevent comorbidities, obesity, and adverse effects of medicine. Symptoms from RMDs like pain, fatigue and deformed joints can also affect the intake of food. The presentation will outline some of the nutritional needs of people with RMDs, how The Danish Reumatism Association can support them, and also give examples of how RMDs can affect nutritional status and how food can be used as therapy. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6196
Abstract B38: Silencing of mortalin, the mitochondrial hsp70, as a novel anticancer treatment strategy
Authors: Muhammad Masarwa, Natalie Donin, Lea Ziporen, Zvi Fishelson
Journal: Cancer Research (2009)

Abstract A handful of monoclonal antibodies have recently been introduced in treatment of hematopoietic malignant neoplasms and solid tumors. The complement system, an important arm of the immune system, is activated following anti-tumor antibody treatment. Complement proteins assemble to form channel-like pores called MAC (Membrane Attack Complexes) that inflict damage to target cells. Unfortunately, cancer cells have many defensive strategies against antibody-dependent complement-mediated cytotoxicity, including MAC shedding by exocytosis. Our recent results have implicated mortalin, the mitochondrial heat shock protein 70, in the removal of the MAC from the cell surface. Mortalin is known to have tumor promoting and anti-apoptotic effects. Our research hypothesis states that mortalin is a vital protector of tumor cells from immune damage. In order to examine this hypothesis, we set up two mouse models of cancer, of K562 erythroleukemia cells in nude mice and EL4 T-lymphoma cells in C57BL/6 mice. Mortalin siRNA was administered to tumor bearing mice with or without concomitant tumor directed antibodies. First, in vitro experiments showed that mortalin siRNA acts synergistically with anti-cancer antibodies in lysis of tumor cells. In vitro mortalin silencing in tumor cells by siRNA and then injection of the cells into mice demonstrated reduced tumor growth, relative to cells pretreated with scrambled siRNA. Mortalin silencing in vivo by intratumoral or intravenous injection of mortalin siRNA led to a significant decrease in tumor growth rate. Furthermore, mortalin siRNA also reduced tumor blood supply and caused tumor necrosis. Growth rate of EL4 and K562 tumors was also significantly inhibited by injection of the mortalin inhibitor MKT-077. Mortalin inhibition in tumors may thus be regarded as a novel adjuvant treatment to immunotherapy. Citation Information: Cancer Res 2009;69(23 Suppl):B38.